Core Viewpoint - The project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," completed with the participation of Yuanzi Gaoke Co., Ltd., has won the first prize of the Beijing Medical Science and Technology Award this year [1] Group 1: Project Significance - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a 5-year survival rate of less than 50% [1] - The project addresses a significant public health issue affecting children's health in China, focusing on the challenges posed by neuroblastoma, referred to as the "king of childhood cancers" [1] Group 2: Technological Innovation - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, after ten years of systematic research [1] - It has developed a multimodal, low-dose, and short-duration nuclear medicine molecular imaging precision diagnosis and treatment system for neuroblastoma, contributing Chinese wisdom and solutions to this global challenge [1]